Medigen Vaccine Biologics Corp.
Industry Group: Pharmaceuticals
Country/Region: Taiwan
Identifier: ROCO:6547
Medigen Vaccine Biologics Corp is a biopharmaceutical company focusing on developing and producing vaccines and biologics. It is engaged in developing IP-protected cell-culture technologies for vaccine manufacturing. The company develops vaccines and affordable biosimilars to prevent regional infectious diseases. The group generates revenue from manufacturing and selling a range of Covid-19 vaccines and Covid-19 test kits and provides technical services on cellular therapy product quality and cell culture tests.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 355 out of 851
Universe
Global Universe 9425 out of 15104
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
EUROAPI SA |
19.2
Low
|
72 out of 851 |
XOMA Royalty Corp. |
26.6
Medium
|
260 out of 851 |
Medigen Vaccine Biologics Corp. |
28.2
Medium
|
355 out of 851 |
Tango Therapeutics, Inc. |
29.6
Medium
|
420 out of 851 |
BIONEER Corp. |
37.3
High
|
753 out of 851 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Medigen Vaccine Biologics Corp.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Medigen Vaccine Biologics Corp.'s Management of ESG Material Risk is Average
How do the ESG Risk Ratings work?
Controversy Rating
Highest Controversy level that has impacted Medigen Vaccine Biologics Corp.'s ESG Risk Rating in the last three years
Highest Controversy Level